These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11440276)

  • 1. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors.
    Davis MI; Wilson SH; Grant MB
    Horm Metab Res; 2001 May; 33(5):295-9. PubMed ID: 11440276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis.
    Dasgupta P
    Pharmacol Ther; 2004 Apr; 102(1):61-85. PubMed ID: 15056499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogues as drug therapies for retinopathies.
    Grant MB; Caballero S
    Drugs Today (Barc); 2002 Nov; 38(11):783-91. PubMed ID: 12582462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinal photocoagulation does not influence intraocular levels of IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy-evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation?
    Spranger J; Möhlig M; Osterhoff M; Bühnen J; Blum WF; Pfeiffer AF
    Horm Metab Res; 2001 May; 33(5):312-6. PubMed ID: 11440279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment of diabetic retinopathy.
    Lang GE
    Ophthalmologica; 2007; 221(2):112-7. PubMed ID: 17380065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of somatostatin receptor ligands in obesity and diabetic complications.
    Boehm BO; Lustig RH
    Best Pract Res Clin Gastroenterol; 2002 Jun; 16(3):493-509. PubMed ID: 12079271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of modulation of GH/IGF-I axis in the development of diabetic proliferative retinopathy.
    Genovese S; Riccardi G
    J Endocrinol Invest; 2003; 26(8 Suppl):114-6. PubMed ID: 15233225
    [No Abstract]   [Full Text] [Related]  

  • 8. Somatostatin in diabetic retinopathy.
    Croxen R; Baarsma GS; Kuijpers RW; van Hagen PM
    Pediatr Endocrinol Rev; 2004 Aug; 1 Suppl 3():518-24. PubMed ID: 16444186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus and retinopathy.
    Gargiulo P; Giusti C; Pietrobono D; La Torre D; Diacono D; Tamburrano G
    Dig Liver Dis; 2004 Feb; 36 Suppl 1():S101-5. PubMed ID: 15077918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Somatostatin analogues: a therapeutic tool in proliferative diabetic retinopathy?].
    Vialettes B; Mallet B
    Journ Annu Diabetol Hotel Dieu; 1992; ():63-70. PubMed ID: 1353800
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy.
    Spranger J; Bühnen J; Jansen V; Krieg M; Meyer-Schwickerath R; Blum WF; Schatz H; Pfeiffer AF
    Horm Metab Res; 2000 May; 32(5):196-200. PubMed ID: 10871161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth factors and diabetic retinopathy.
    Paques M; Massin P; Gaudric A
    Diabetes Metab; 1997 Apr; 23(2):125-30. PubMed ID: 9137900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy.
    Wilkinson-Berka JL; Wraight C; Werther G
    Curr Med Chem; 2006; 13(27):3307-17. PubMed ID: 17168853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of diabetic retinopathy with somatostatin analogues.
    Palii SS; Caballero S; Shapiro G; Grant MB
    Expert Opin Investig Drugs; 2007 Jan; 16(1):73-82. PubMed ID: 17155855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current approaches and perspectives in the medical treatment of diabetic retinopathy.
    Porta M; Allione A
    Pharmacol Ther; 2004 Aug; 103(2):167-77. PubMed ID: 15369682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.
    Raynor K; Murphy WA; Coy DH; Taylor JE; Moreau JP; Yasuda K; Bell GI; Reisine T
    Mol Pharmacol; 1993 Jun; 43(6):838-44. PubMed ID: 8100350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of long-acting somatostatin analogue treatment in diabetic retinopathy.
    Boehm BO
    Dev Ophthalmol; 2007; 39():111-121. PubMed ID: 17245082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiology of somatostatin receptors.
    Guillermet-Guibert J; Lahlou H; Cordelier P; Bousquet C; Pyronnet S; Susini C
    J Endocrinol Invest; 2005; 28(11 Suppl International):5-9. PubMed ID: 16625838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.